ジスキネジア:治療薬開発パイプライン分析

◆英語タイトル:Dyskinesia - Pipeline Review, H2 2017
◆商品コード:GMDHC9708IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2017年9月12日
◆ページ数:147
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界におけるジスキネジアの治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・ジスキネジアの概要
・ジスキネジア治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・ジスキネジアパイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・ジスキネジア治療薬開発に取り組んでいる企業:企業別製品パイプライン
・ジスキネジア治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Dyskinesia – Pipeline Review, H2 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia – Pipeline Review, H2 2017, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.

Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Dyskinesia – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 13, 4, 17 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Dyskinesia – Overview 8
Dyskinesia – Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 17
Dyskinesia – Therapeutics Assessment 18
Assessment by Target 18
Assessment by Mechanism of Action 21
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Dyskinesia – Companies Involved in Therapeutics Development 28
Adamas Pharmaceuticals Inc 28
Addex Therapeutics Ltd 28
Advicenne SA 29
Avanir Pharmaceuticals Inc 29
Bionomics Ltd 29
Catalyst Biosciences Inc 30
Cavion LLC 30
Clevexel Pharma SAS 31
EpiVax Inc 31
Heptares Therapeutics Ltd 31
Ipsen SA 32
Merz Pharma GmbH & Co KgaA 32
Neurim Pharmaceuticals Ltd 33
Neurocrine Biosciences Inc 33
Neurolixis Inc 33
Osmotica Pharmaceutical Corp 34
Phenomenome Discoveries Inc 34
Sage Therapeutics Inc 35
SciFluor Life Sciences LLC 35
SOM Biotech SL 35
Synchroneuron Inc 36
Dyskinesia – Drug Profiles 37
(dextromethorphan + quinidine sulfate) – Drug Profile 37
A-2M13677 – Drug Profile 42
abobotulinumtoxinA – Drug Profile 43
acamprosate calcium SR – Drug Profile 47
amantadine hydrochloride ER – Drug Profile 49
amantadine hydrochloride ER – Drug Profile 59
AT-127 – Drug Profile 60
AT-326 – Drug Profile 61
AT-403 – Drug Profile 62
befiradol – Drug Profile 63
brexanolone – Drug Profile 65
CVXL-0107 – Drug Profile 74
CX-8998 – Drug Profile 75
cycloserine – Drug Profile 76
dipraglurant IR – Drug Profile 77
Drug for Dyskinesia – Drug Profile 82
Drug for Tardive Dyskinesia – Drug Profile 83
Drugs for Dyskinesia – Drug Profile 84
Gene Therapy to Inhibit TRH for Dyskinesia – Drug Profile 85
HTL-14242 – Drug Profile 86
incobotulinumtoxin A – Drug Profile 87
IRL-790 – Drug Profile 92
JM-010 – Drug Profile 93
MLR-1019 – Drug Profile 95
NBI-640756 – Drug Profile 96
Neu-120 – Drug Profile 97
Neu-240 – Drug Profile 98
onabotulinumtoxinA – Drug Profile 99
PCT-3010 – Drug Profile 100
PPI-1011 – Drug Profile 101
RNAi Gene Therapy to Inhibit NURR1 for Dyskinesia – Drug Profile 102
SAGE-217 – Drug Profile 103
SK-609 – Drug Profile 107
Small Molecule for Dyskinesia – Drug Profile 108
Small Molecule for Dyskinesia – Drug Profile 109
Small Molecules for Neurodegenerative Disease – Drug Profile 110
Small Molecules to Antagonize GPCR for Central Nervous System Diseases – Drug Profile 111
Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia – Drug Profile 112
Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders – Drug Profile 113
Small Molecules to Antagonize mGluR5 for Dyskinesia – Drug Profile 114
Small Molecules to Target Ion Channels for CNS Disorders – Drug Profile 115
SOM-3355 – Drug Profile 116
TC-8831 – Drug Profile 117
tetrabenazine – Drug Profile 118
valbenazine tosylate – Drug Profile 119
Dyskinesia – Dormant Projects 127
Dyskinesia – Discontinued Products 129
Dyskinesia – Product Development Milestones 130
Featured News & Press Releases 130
Appendix 143
Methodology 143
Coverage 143
Secondary Research 143
Primary Research 143
Expert Panel Validation 143
Contact Us 143
Disclaimer 144

List of Tables
Number of Products under Development for Dyskinesia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Dyskinesia - Pipeline by Adamas Pharmaceuticals Inc, H2 2017
Dyskinesia - Pipeline by Addex Therapeutics Ltd, H2 2017
Dyskinesia - Pipeline by Advicenne SA, H2 2017
Dyskinesia - Pipeline by Avanir Pharmaceuticals Inc, H2 2017
Dyskinesia - Pipeline by Bionomics Ltd, H2 2017
Dyskinesia - Pipeline by Catalyst Biosciences Inc, H2 2017
Dyskinesia - Pipeline by Cavion LLC, H2 2017
Dyskinesia - Pipeline by Clevexel Pharma SAS, H2 2017
Dyskinesia - Pipeline by EpiVax Inc, H2 2017
Dyskinesia - Pipeline by Heptares Therapeutics Ltd, H2 2017
Dyskinesia - Pipeline by Ipsen SA, H2 2017
Dyskinesia - Pipeline by Merz Pharma GmbH & Co KgaA, H2 2017
Dyskinesia - Pipeline by Neurim Pharmaceuticals Ltd, H2 2017
Dyskinesia - Pipeline by Neurocrine Biosciences Inc, H2 2017
Dyskinesia - Pipeline by Neurolixis Inc, H2 2017
Dyskinesia - Pipeline by Osmotica Pharmaceutical Corp, H2 2017
Dyskinesia - Pipeline by Phenomenome Discoveries Inc, H2 2017
Dyskinesia - Pipeline by Sage Therapeutics Inc, H2 2017
Dyskinesia - Pipeline by SciFluor Life Sciences LLC, H2 2017
Dyskinesia - Pipeline by SOM Biotech SL, H2 2017
Dyskinesia - Pipeline by Synchroneuron Inc, H2 2017
Dyskinesia - Dormant Projects, H2 2017
Dyskinesia - Dormant Projects, H2 2017 (Contd..1), H2 2017
Dyskinesia - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Dyskinesia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

【レポートのキーワード】

ジスキネジア

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ジスキネジア:治療薬開発パイプライン分析(Dyskinesia - Pipeline Review, H2 2017)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆